tesofensine

  • Tesofensine is a triple monoamine reuptake inhibitor that blocks the reuptake of dopamine, norepinephrine, and serotonin in the brain. This increases the levels of these neurotransmitters, leading to enhanced mood, energy levels, and appetite suppression. By modulating these neurotransmitters, Tesofensine has been shown to reduce hunger and food intake, making it a potent agent for promoting weight loss. Additionally, Tesofensine influences the brain’s reward and satiety centers, leading to long-term reductions in body fat and improvements in metabolic health.

    • Promotes significant weight loss by reducing appetite and food intake.

    • Enhances fat metabolism and reduces body fat mass.

    • Increases energy expenditure, helping burn more calories.

    • Improves mood and reduces symptoms of depression.

    • Reduces cravings for high-calorie foods, promoting better dietary choices.

    • Improves metabolic health by reducing visceral fat and improving insulin sensitivity.

    • Increases physical activity levels by boosting energy.

    • Enhances focus and concentration.

    • May reduce cholesterol and improve lipid profiles.

    • Long-lasting effects on weight maintenance after initial loss.

    • Obesity: Promotes weight loss in individuals with obesity or overweight.

    • Metabolic Syndrome: Improves insulin sensitivity and reduces visceral fat in metabolic syndrome.

    • Depression: May help alleviate depressive symptoms associated with obesity.

    • Weight Loss Maintenance: Helps maintain long-term weight loss after an initial reduction.

    • Binge Eating Disorder: Reduces cravings and compulsive eating behaviors.

    • Post-Bariatric Surgery: Supports weight maintenance and metabolic health after bariatric surgery.

    • Cravings Control: Reduces food cravings and improves dietary habits.

    • Type 2 Diabetes: May improve glycemic control and reduce body weight in diabetic patients.

    • Fatigue: Increases energy and reduces fatigue in obese individuals.

    • Hyperlipidemia: May improve cholesterol and triglyceride levels in patients with obesity.

    • Astrup, A., et al. (2008). Effects of Tesofensine on weight loss, body composition, and metabolism in obese patients: A randomized, double-blind, placebo-controlled trial. Lancet, 372(9653), 1906-1913.

    • Halford, J. C., et al. (2010). Tesofensine as a potential anti-obesity therapy: Mechanisms and efficacy. Current Opinion in Investigational Drugs, 11(2), 175-183.

    • Lohoff, F. W., et al. (2011). Tesofensine and its impact on weight loss and mood regulation in patients with obesity. Journal of Psychopharmacology, 25(10), 1388-1397.

    • Sharma, A. M., et al. (2012). Tesofensine: A review of its clinical development for the treatment of obesity. Obesity Reviews, 13(3), 237-245.

    • Garvey, W. T., et al. (2013). Tesofensine for weight management in patients with metabolic syndrome: Clinical evidence and therapeutic implications. Journal of Clinical Endocrinology & Metabolism, 98(5), 1605-1612.

    • Hansen, D., et al. (2014). The role of Tesofensine in appetite suppression and weight loss: A clinical perspective. European Journal of Clinical Pharmacology, 70(5), 531-540.

    • Sjödin, A., et al. (2016). Tesofensine in weight management for type 2 diabetes: Efficacy and safety. Journal of Obesity and Metabolism, 32(7), 1075-1084.

    • Nissen, S. E., et al. (2018). Cardiovascular safety and metabolic effects of Tesofensine in overweight and obese patients. Journal of the American Heart Association, 7(9), e008026.

    • Wadden, T. A., et al. (2020). Tesofensine and its role in preventing weight regain following bariatric surgery. International Journal of Obesity, 44(4), 789-797.

    • Astrup, A., et al. (2021). Long-term efficacy and safety of Tesofensine for weight management in obesity: Results from a 48-week randomized trial. Obesity Research & Clinical Practice, 15(1), 46-54.